Health

States developing public options may offer the federal government valuable lessons in expanding access to care at a lower cost.

The COVID-19 pandemic raises questions about how decision-makers should distribute medical resources.

With medical systems overwhelmed during the pandemic, telemedicine could be here to stay.

FDA releases guidance on using blood from recovered COVID-19 patients to treat new cases.

Coronavirus immunity certificates could permit recovered persons to escape lockdown restrictions.

Regulators and policymakers review old rules and propose new guidelines for rationing ventilators.

FDA clarifies its generic drug approval process in an effort to encourage market competition.

To curb overdoses and drug trafficking, the DEA proposes regulations for a chemical precursor to fentanyl.

U.S. food stamp programs grapple with a new wave of scrutiny.

Critics of a proposed rule to import drugs from Canada cite safety concerns and other potential problems.

The federal government seeks authority over stem cell treatments but risks thwarting medical advancement.

Responding to the coronavirus outbreak, a federal agency relaxes requirements on medical device manufacturers.